Intravenous fibrinolysis eligibility: A survey of stroke clinicians' practice patterns and review of the literature

Journal of Stroke and Cerebrovascular Diseases

Volumn 23, Issue 8, 2014, Pages 2130-2138

  De Los Rios, Felipe ^a,f   Kleindorfer, Dawn O ^a   Guzik, Amy ^b   Ortega Gutierrez, Santiago ^e   Sangha, Navdeep ^c   Kumar, Gyanendra ^d   Grotta, James C ^c   Lee, Jin Moo ^d   Meyer, Brett C ^b   Schwamm, Lee H ^g   Khatri, Pooja ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f Sanna Healthcare Network   (Peru)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

infarction; rtPA; Stroke; stroke treatment; thrombolysis; tissue plasminogen activator

Indexed keywords

ALTEPLASE; WARFARIN; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

AGE; ARTERY OCCLUSION; ARTICLE; BRAIN ISCHEMIA; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DECISION MAKING; DIABETES MELLITUS; DISABILITY; DISEASE SEVERITY; DRUG CONTRAINDICATION; FIBRINOLYTIC THERAPY; HEALTH SURVEY; HIGH VOLUME HOSPITAL; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRACRANIAL ANEURYSM; MEDICAL EXPERT; MEDICAL HISTORY; MEDICAL SOCIETY; NATIONAL HEALTH ORGANIZATION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; SEIZURE; SYMPTOM; AGED; AGING; DRUG EFFECTS; FEMALE; INFORMATION PROCESSING; LITERATURE; MALE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PHYSICIAN; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA; STROKE; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; DATA COLLECTION; ELIGIBILITY DETERMINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PHYSICIANS; PRACTICE PATTERNS, PHYSICIANS'; RECOMBINANT PROTEINS; REVIEW LITERATURE AS TOPIC; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84908146640     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2014.03.024     Document Type: Article

References (37)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group The New England journal of medicine 333 1995 1581
2. W. Hacke, M. Kaste, and E. Bluhmki Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke NEnglJMed 359 2008 1317 1329
3. group ISTc P. Sandercock, and J.M. Wardlaw The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial Lancet 379 2012 2352 2363
4. J.M. Wardlaw, V. Murray, and E. Berge Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis Lancet 379 2012 2364 2372
5. O. Adeoye, R. Hornung, and P. Khatri Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years Stroke 42 2011 1952 1955
6. E.C. Jauch, J.L. Saver, and H.P. Adams Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 44 2013 870 947
7. D. Tong Are all IV thrombolysis exclusion criteria necessary? Being SMART about evidence-based medicine Neurology 76 2011 1780 1781
8. N. Wiegand, R. Luthya, and B. Vogel Intravenous thrombolysis for ischaemic stroke is also safe and efficient without a specialised neuro-intensive care unit Swiss Medical Weekly 134 2004 14 17
9. L. Suissa, E. Bozzolo, and S. Lachaud Intravenous thrombolysis with rt-PA in stroke: experience of the Nice stroke unit Rev Neurol 165 2009 471 478
10. C.A. Cronin, N. Shah, and T. Morovati No increased risk of symptomatic intracerebral hemorrhage after thrombolysis in patients with European Cooperative Acute Stroke Study (ECASS) exclusion criteria Stroke 43 2012 1684 1686
11. M. Rubiera, M. Ribo, and E. Santamarina Is it time to reassess the SITS-MOST criteria for thrombolysis? A comparison of patients with and without SITS-MOST exclusion criteria Stroke 40 2009 2568 2571
12. M. Guillan, A. Alonso-Canovas, and J. Garcia-Caldentey Off-label intravenous thrombolysis in acute stroke European Journal of Neurology 19 2012 390 394
13. A. Meretoja, J. Putaala, and T. Tatlisumak Off-Label thrombolysis is not associated with poor outcome in patients with stroke Stroke 41 2010 1450 1458
14. A. Aleu, P. Mellado, and C. Lichy Hemorrhagic complications after off-label thrombolysis for ischemic stroke Stroke 38 2007 417 422
15. J. De Keyser, Z. Gdovinova, and M. Uyttenboogaart Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations Stroke 38 2007 2612 2618
16. I.L. Katzan, M.D. Hammer, A.J. Furlan Cleveland Clinic Health System Stroke Quality Improvement T Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update Stroke 34 2003 799 800
17. I.L. Katzan, A.J. Furlan, and L.E. Lloyd Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience JAMA 283 2000 1151 1158
18. H.P. Adams Jr., G. del Zoppo, and M.J. Alberts Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association, Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke 38 2007 1655 1711
19. G.J. Del Zoppo, J.L. Saver, and E.C. Jauch Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association Stroke 40 2009 2945
20. O.Y. Chernyshev, S. Martin-Schild, and K.C. Albright Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia Neurology 74 2010 1340 1345
21. M. Guillan, A. Alonso-Canovas, and J. Gonzalez-Valcarcel Stroke mimics treated with thrombolysis: further evidence on safety and distinctive clinical features Cerebrovascular Diseases 34 2012 115 120
22. F. de Los Rios la Rosa, J. Khoury, and B.M. Kissela Eligibility for intravenous recombinant tissue-type plasminogen activator within a population: the effect of the European Cooperative Acute Stroke Study (ECASS) III Trial Stroke 43 2012 1591 1595
23. N.J. Edwards, H. Kamel, and S.A. Josephson The safety of intravenous thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms: a case series and review of the literature Stroke 43 2012 412 416
24. K.N. Sheth, N. Shah, and T. Morovati Intravenous rt-PA is not associated with increased risk of hemorrhage in patients with intracranial aneurysms Neurocrit Care 17 2012 199 20325
25. J.T. Kim, M.S. Park, and W. Yoon Detection and significance of incidental unruptured cerebral aneurysms in patients undergoing intravenous thrombolysis for acute ischemic stroke Journal of neuroimaging 22 2012 197 200
26. D.A. De Silva, J.J.F. Manzano, and H.M. Chang Reconsidering recent myocardial infarction as a contraindication for IV stroke thrombolysis Neurology 76 2011 1838 1840
27. S.E. Kasner, C.E. Villar-Cordova, and D. Tong Hemopericardium and cardiac tamponade after thrombolysis for acute ischemic stroke Neurology 50 1998 1857 1859
28. S. Prabhakaran, J. Rivolta, and J.R. Vieira Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke Arch Neurol 67 2010 559 563
29. Y. Xian, L. Liang, and E.E. Smith Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator JAMA 307 2012 2600 2608
30. M.D. Vergouwen, L.K. Casaubon, and R.H. Swartz Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator Stroke 42 2011 1041 1045
31. K.R. Lees, E. Bluhmki, and R. von Kummer Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials Lancet 375 2010 1695 1703
32. W. Hacke, G. Donnan, and C. Fieschi Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials Lancet 363 2004 768 774
33. M. Grigoryan, C.E. Tung, and G.W. Albers Role of diffusion and perfusion MRI in selecting patients for reperfusion therapies Neuroimaging Clin N Am 21 2011 247 257
34. K.A. Dani, R.G.R. Thomas, and F.M. Chappell Systematic review of perfusion imaging with computed tomography and magnetic resonance in acute ischemic stroke: heterogeneity of acquisition and postprocessing parameters: a Translational Medicine Research Collaboration Multicentre Acute Stroke Imaging Study Stroke 43 2012 563 566
35. J. Sobesky Refining the mismatch concept in acute stroke: lessons learned from PET and MRI J of Cereb Blood Flow Metab 32 2012 1416 1425
36. C.S. Kidwell, R. Jahan, and J. Gornbein A Trial of Imaging Selection and Endovascular Treatment for Ischemic Stroke N Engl J Med 368 2013 914 923
37. N.K. Hills, and S. Claiborne Johnston Why are eligible thrombolysis candidates left untreated? Am J Prev Med 31 2006 S210 S216